Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors

NCT07284186 is registered in ClinicalTrials.gov with Plexium, Inc. as lead sponsor.

NCT NCT07284186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Plexium, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2025
Completion date
September 30, 2030
Enrollment
155 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma, gastroesophageal junction (gej) adenocarcinoma, gastroesophageal junction squamous cell carcinoma, metastatic solid tumor, non-small cell lung carcinoma, smarca4 mutation